CLINICAL TRIAL

NCT01496040

Interventional

Phase 1/2

Neuroophthalmology RED

Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65

Rare Eye Disease concerned by the trial :
Leber Congenital Amaurosis

Status of the trial : completed

Orphan drug recognition : N/A

Inclusion criteria : click here to see detailed criteria

Exclusion criteria : click here to see detailed criteria

Inclusion opening date : 01/09/2011

Inclusion closing date (previsional) : 01/08/2014

Children ☑

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Clinique Ophtalmologique
CHU de Nantes
5 allée de l'île gloriette
44093 Nantes Cedex 01



Principal investigator name :
Michel Weber

Other investigators :
None

Funder type : Other

More informations